Translational and clinical immunologyDouble-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies
Under a Creative Commons license
open access
Graphical abstract
Key words
Primary antibody defects
azithromycin
antibiotic prophylaxis
respiratory exacerbation
chronic obstructive pulmonary disease
Abbreviations used
AE
Adverse event
CF
Cystic fibrosis
COPD
Chronic obstructive pulmonary disease
CVID
Common variable immunodeficiency
HR
Hazard risk
HRQoL
Health-related quality of life
PAD
Primary antibody deficiency
PID
Primary immunodeficiency disease
SF-36
Short Form 36
SGRQ
Saint George Respiratory Questionnaire
XLA
X-linked agammaglobulinemia
Cited by (0)
Clinical Trials no. EUDRACT 2011-004351-39 was funded by the Agenzia Italiana del Farmaco (AIFA). The Rome PID Clinical Research Center is supported by the Jeffrey Modell Foundation.
Disclosure of potential conflict of interest: A. Pecoraro and I. Quinti have received consultation fees and grants from Shire, CSL Behring, Octapharma, and Kedrion. A. Matucci and C. Agostini have received consultation fees by Shire, Roche, CSL Behring, Octapharma, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.
Clinical Trials no. EUDRACT 2011-004351-39.
- ∗
These authors contributed equally to this work.
© 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.